Ratings Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-22 pm EDT			5-day change	1st Jan Change
0.915 ^USD	+0.58%		+1.79%	-35.11%

May. 13	Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13	Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
LUCID DIAGNOSTICS INC.	-35.11%	45.58M	-
SHOCKWAVE MEDICAL, INC.	+75.28%	12.54B	B-
PENUMBRA, INC.	-20.90%	7.71B	C+
MASIMO CORPORATION	+8.01%	6.72B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+12.49%	5.38B	D+
APT MEDICAL INC.	+37.02%	4.89B	-
GETINGE AB	-17.01%	4.71B	B
ASAHI INTECC CO., LTD.	-25.08%	3.75B	B-
INARI MEDICAL, INC.	-26.57%	2.77B	C
NOVOCURE LIMITED	+58.74%	2.55B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes